Focus: Longevity Biotech is a public biotechnology company headquartered in Philadelphia specializing in synthetic peptides for neurological disorders. The company is early-stage with a focused pipeline targeting Parkinson's disease.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Longevity Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Longevity Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Longevity Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Insilico Medicine Takes Lead Role in Major Longevity Biotech Conference at Harvard - TipRanks
Insilico Medicine Takes Lead Role in Major Longevity Biotech Conference at Harvard TipRanks
Insilico Medicine to Present Longevity and AI Drug Innovations at BIO Asia-Taiwan 2026 - Bioengineer.org
Insilico Medicine to Present Longevity and AI Drug Innovations at BIO Asia-Taiwan 2026 Bioengineer.org
Future Biotech Expo brings longevity into focus - Longevity.Technology
Future Biotech Expo brings longevity into focus Longevity.Technology
Longevity medicine's do-or-die moment - Axios
Longevity medicine's do-or-die moment Axios
The New Billionaire Bet Isn't AI — It's Longevity Biotech - Forbes
The New Billionaire Bet Isn't AI — It's Longevity Biotech Forbes
Daewoong acquires Turn Bio age-reversal assets - Longevity.Technology
Daewoong acquires Turn Bio age-reversal assets Longevity.Technology
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo